Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)

Trial Profile

Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Regorafenib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Biliary cancer
  • Focus Adverse reactions
  • Acronyms BREGO
  • Most Recent Events

    • 20 Jan 2018 Results of phase Ib part of this study (n=22) presented at the 2018 Gastrointestinal Cancers Symposium.
    • 17 Jan 2018 According to a Bayer media release, data will be present at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium 2018.
    • 04 Jul 2015 Results presented at the 17th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top